LLY · 8-K · 20261029PR000104

China NRDL Pricing Impact

ELI LILLY & Co · 2026-10-29 · Importance 77 · Surprise 82

China’s National Reimbursement Drug List (NRDL) inclusion for Mounjaro in Q1 2026 was identified as a primary driver of lower realized prices outside the U.S. In Q3 2026, revenue outside the U.S. was $9.3 billion, with realized prices down 29% year over year, a decline exceeding the stated 10% materiality threshold. Mounjaro revenue outside the U.S. increased 93% to $5.7 billion, primarily from volume growth, partially offset by lower realized prices associated with NRDL inclusion.

Key facts

• Lower realized prices outside the U.S. in Q3 2026 were driven primarily by Mounjaro's inclusion on China's NRDL. source